In the maintenance phase of opioid withdrawal, the primary objective is to stabilize the patient’s condition and prevent relapse. Among the given options, the drug that is commonly used for maintenance therapy in opioid withdrawal is Buprenorphine.
Buprenorphine is favored due to its partial agonist properties at the mu-opioid receptor and antagonist properties at the kappa-opioid receptor. This dual action provides relief from withdrawal symptoms and reduces cravings while having a lower risk of abuse compared to full agonists like methadone.
Let's briefly examine the other options to understand why they are not suitable for maintenance therapy in opioid withdrawal:
Therefore, Buprenorphine is the appropriate choice for the maintenance phase of opioid withdrawal due to its efficacy in reducing cravings and relapse risk.
The normal pH of arterial blood is:
Which enzyme is deficient in Gaucher’s disease?
Which of the following cranial nerves is responsible for the motor innervation of the muscles of mastication?
The anticoagulant effect of heparin is monitored using:
The causative agent of malaria is: